Overview

Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Status:
Withdrawn

Trial end date:
2018-07-11

Target enrollment:

Participant gender:

Summary

The overall goal of this study is to identify a safe dose of metformin, in combination with oligomeric procyanidin complex (OPC) for pharmacologic reduction of AGE levels in patients with prostate cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Medical University of South Carolina

Treatments:

Metformin
Proanthocyanidin
Procyanidin